Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. - Wikidata - awgldk - TriplyDB

Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.

Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.

http://www.wikidata.org/entity/Q37416887

about

Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease.The use of fibroblast growth factor 23 testing in patients with kidney disease.CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: a crossover study Effects of lanthanum carbonate versus calcium carbonate on vascular stiffness and bone mineral metabolism in hemodialysis patients with type 2 diabetes mellitus: a randomized controlled trial.Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.Decline of Renal Function and Progression of Left Ventricular Hypertrophy Are Independently Determined in Chronic Kidney Disease Stages 3-5.Pathophysiology of the chronic kidney disease-mineral bone disorder.Con: Phosphate binders in chronic kidney disease Relationship of dietary phosphate intake with risk of end-stage renal disease and mortality in chronic kidney disease stages 3-5: The Modification of Diet in Renal Disease Study.Fibroblast growth factor-23 and chronic allograft injury in pediatric renal transplant recipients: a Midwest Pediatric Nephrology Consortium study.The Kidney-Vascular-Bone Axis in the Chronic Kidney Disease-Mineral Bone Disorder.Pro: Should phosphate binders be used in chronic kidney disease stage 3-4?The effect of magnesium supplementation on vascular calcification in chronic kidney disease-a randomised clinical trial (MAGiCAL-CKD): essential study design and rationale.Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.Nicotinamide and phosphate homeostasis in chronic kidney disease.Potential application of klotho in human chronic kidney disease.The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology.Medial and intimal calcification in chronic kidney disease: stressing the contributions.Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.Blood pressure variability is independent of systolic pressure in adolescent and young adult patients undergoing hemodialysis.Changes With Lanthanum Carbonate, Calcium Acetate, and Phosphorus Restriction in CKD: A Randomized Controlled Trial.TGF-Beta Signaling in Bone with Chronic Kidney Disease

P2860

Q33791650-2E6E4A11-5DEB-45B0-BFFB-2E2B6E6F255E Q33835743-BEE71AB7-0724-4724-80B6-2D81ADE03CE0 Q33974636-A742ED7C-B25F-4C5A-B75E-4F815207AA65 Q34336027-238C1E0F-1671-4841-B0CA-E679EDBE3C5B Q36010396-3AB03FBB-B02D-4103-9BBC-6911AFB4D21A Q36104887-2816DDE1-F7E4-4489-9131-914D3B41E927 Q36283221-67931BE6-4390-4F5B-A77C-F55FAA4366C2 Q36425115-6E16FD9C-9C54-4284-9C3F-548540F51563 Q36497902-3CA918AC-7D97-4AD1-99B1-D78415D147B2 Q36746618-964B2350-5855-415D-823D-9C571C39526C Q36759150-BE9463CA-99BD-4DEB-BD19-B263408080D0 Q38584122-D935F1C1-FE76-4118-8B15-4D8AB909E04E Q38673170-937814EE-2310-4ABA-8610-FDA3ACEE062E Q38711321-5C9FDE6A-C4B9-476A-A636-92D2A4C229C8 Q38828902-7C062DCC-8294-4797-8D8D-B404E3B3E83F Q38842982-4C2B5E22-897F-451D-8385-8F3D4C212665 Q39003568-428CD3B6-A007-4840-8058-CEEA5D6FDCDB Q39101623-0C882C83-EFE4-4170-84E3-F6AD8D5D252C Q42875539-8EA19E1C-2634-4D21-9C26-6FD957E69DA7 Q48226016-8D34E985-B664-4397-AC7D-D0F74B0EEE20 Q49796209-7BD05CDB-3145-4C9D-A978-6DADBF4E9376 Q55509854-E15B7DD9-CE15-4992-BC11-C822AE6CA735 Q58789309-965DD856-5639-4804-AC6E-7A8F5F54A879

P2860

Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.

http://www.wikidata.org/entity/Q37416887

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effects of phosphate binder th ...... -stage chronic kidney disease.

@en

Effects of phosphate binder th ...... -stage chronic kidney disease.

@nl

type

label

Effects of phosphate binder th ...... -stage chronic kidney disease.

@en

Effects of phosphate binder th ...... -stage chronic kidney disease.

@nl

prefLabel

Effects of phosphate binder th ...... -stage chronic kidney disease.

@en

Effects of phosphate binder th ...... -stage chronic kidney disease.

@nl

P1433

Q37416887-DFB67E96-9010-4C1F-9EC0-AD7CE4E6CAF0

P1476

Q37416887-3C8F9A8B-1431-4E23-B6B4-23C0231BBD5B

P2093

Q37416887-1DB27986-794C-41E1-8D18-832E43722CF6

Q37416887-26284CA7-6092-4202-9543-4EAB9ECC3862

Q37416887-42F2DFE1-2F53-4C74-A84C-DAB7C481680F

Q37416887-4345CABA-C76F-4E93-A6E6-8078ED2ACFA1

Q37416887-470F7A67-C883-4140-B823-44EE1802D1C1

Q37416887-C414CF8D-7089-42EA-A850-9E905AD6878C

Q37416887-EA47D4DA-B55A-4D4E-8B15-3803DF2D61F8

Q37416887-EB5D052D-9464-451C-A3C8-FDE733C60D93

P2860

Q37416887-00D8C42A-A614-4256-AEBE-498273B139FE

Q37416887-0DB20A61-3B8D-4E58-8AE8-1DDB2065EA4C

Q37416887-0E69AD66-7940-4417-893C-C33FA87C5F93

Q37416887-1048FE7D-C115-4D6F-96F3-3D83F0237B8B

Q37416887-13BD8ED5-AA7B-4A1E-B775-8FE377851936

Q37416887-14F0578A-C086-48F4-9728-76233B0D1312

Q37416887-2499E185-2F2F-4DA5-95DD-9AA6E2B63DCD

Q37416887-2F58CC91-4A22-44E8-9AB7-139EE8789964

Q37416887-315E6562-AA69-4C4E-9BE3-2C55B6304799

Q37416887-32C8441D-D0FC-415B-ABBA-65BF46A4795A

P304

Q37416887-C92AF68B-D57F-41CB-8F74-421D0486F32D

P31

Q37416887-98115C83-AC4E-4095-A064-A1B2067810AA

P356

Q37416887-5A6C411A-62F3-4D99-B62F-14066FFD0048

P433

Q37416887-323CC7A4-6005-46E3-A5CF-F73E48F64E71

P478

Q37416887-DEE31324-2E39-48F5-A2BD-45EB6FAE2A2A

P50

Q37416887-21EEE5FC-24D3-4DD3-A11E-19F2CE4214B1

Q37416887-C69AB12C-3D32-478E-B0A2-DCAA12901BFF

P577

Q37416887-5B41DE94-B16C-4C6B-A346-B0BA0432565D

P698

Q37416887-67D01146-E19F-449D-8078-64A54236B8D7

P932

Q37416887-A221CB49-F66D-478D-8805-74082AFC0F4D

P356

P1433

American Journal of Nephrology

P1476

Effects of phosphate binder th ...... y-stage chronic kidney disease

@en

P2093

Andrew J Bierhals

http://www.w3.org/2001/XMLSchema#string

David Windus

http://www.w3.org/2001/XMLSchema#string

Dennis J Dietzen

http://www.w3.org/2001/XMLSchema#string

Keith A Hruska

http://www.w3.org/2001/XMLSchema#string

Marcos Rothstein

http://www.w3.org/2001/XMLSchema#string

Steven C Cheng

http://www.w3.org/2001/XMLSchema#string

Víctor G Dávila-Román

http://www.w3.org/2001/XMLSchema#string

Will Ross

http://www.w3.org/2001/XMLSchema#string

P2860

Arterial calcification in chronic kidney disease: key roles for calcium and phosphate

Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Prevalence of chronic kidney disease in the United States

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.

Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin.

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Impact of aortic stiffness on survival in end-stage renal disease.

Serum phosphorus levels and the spectrum of ankle-brachial index in older men: the Osteoporotic Fractures in Men (MrOS) study

P304

158-167

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000353569

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P50

Lisa de las Fuentes

Michael E Seifert

P577

2013-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23941761

http://www.w3.org/2001/XMLSchema#string

P932

3874122

http://www.w3.org/2001/XMLSchema#string